Europaisches Patentamt
European Patent Office
Office européen des brevets

Publication number: **0 519 144 A1**

EUROPEAN PATENT APPLICATION

Application number: 91500066.5

Int. Cl.: **A61K 9 54**, A61K 31 44

Date of filing: 21.06.91

Date of publication of application:
23.12.92 Bulletin 92/52

Designated Contracting States:
AT BE CH DE DK ES FR GB GR IT LI LU NL SE

Applicant: **ILSAN ILAC VE HAMMADDELERI SANAYI A.S.**
Kore Sehitleri Cad. No. 40
T-80300 Zincirlikuyu, Istambul(TR)

Inventor: **Tanberk, Ergin**
Kalamis Fener Cd. Yelken Ap. 86/39
Istambul(TR)
Inventor: **Memecan, Melih**
Bagdat Cd. Tanyeri, Ap. 421/6
Suadiye-Istambul(TR)
Inventor: **Güngör, Ülkü**
Hülya Sk. 19/1
06700 Gaziosmanpasa, Istambul(TR)
Inventor: **Gül, Handan**
Semsettin Günaltay Cd. Safak
SK 1/7 Erenköy-Istambul(TR)
Inventor: **Moralioglu, Mehmet**
Beylerbeyi Cd. No. 8 Kuzguncuk
Istambul(TR)

Representative: **Alonso Langle, Emilio**
Naciones, 12, 3 piso B
E-28006 Madrid(ES)

New galenic process for omeprazole containing pellets.

A production method for pellets containing Omeprazole performed with an inert core based on sacarose, starch and glucose, said core covered with the micronized and sieved active substance which is in a buffered dispersion, being added with an anionic surface active agent, in order to finally receive an enteric covering in a fluidized bed with HPMC phyiate, diethyl phylate, aceton and ethyl alcohol being afterwards dried to obtain a water content of less than 1% sieved, weighted and encapsulated.

EP 0 519 144 A1

A new production method for enteric coated pellets containing Omeprazole which is coated on an inert core in the form of pH buffered dispersion phase.

Field of invention:

The present invention is related to a new production method of a stable preparation containing Omeprazole for oral administration.

Description of invention:

Omeprazole is a potent inhibitor of gastric acid secretion. Omeprazole is a pyridine benzimidazol derivative with the following total formula $C_{17}H_{19}N_3O_3S$ and a molecular weight of 354.4.

Structure formula:



Omeprazole (1) is readily degradable in acidic enviroments, pH less than 7. Stability profile of 1 is almost the same in solid phase, and is also affected by moisture and organic solvents. The reason why oral dosage forms of Omeprazole have to be formulated as enteric coated dosage form is to protect it from acidic gastric juice. (Ref.US Patent 4.786.505 Nov. 22. 1988) Enteric coated pellets of Omeprazol should reasonably withstand the gastric juice but it must be dissolved rapidly in the small intestine to obtain areasonable bioavailability of course the effect. Several coating met-hods and materials have been used to comply the above mentioned prerequisi-tes of Omeprazole (UK Patent GB 21 89 698)

In this patent application a new process for the preparation of aorally used hard gelatin capsule containing enteric coated Omeprazole pellets is described.

This new enteric coated pellet production process consists of the following four steps.

I.Preparation of inert core by conventional pan coating method

II.Active coating by using rotary type fluidized bed

III.Protective coating by using rotary type fluidized bed.

IV.Enteric coating by using rotary type fluidized bed.

I.The contents of inert core are as following

Saccorose **65-85%**
Corn Starch **15-25%**
Glucose **2-6%**

Particle size distrubution range is arranged to be 90% within 0.71 mm. to 0.85 mm. (in diameter) by suitable sieving. These inert pellets can also be obtained commercially.

II.To obtain a rapid dispersion active (Omeprazoe) substance is micronized and sieved through 150 mesh sieves.

The active substance sieved is dispersed in a buffered aqueous dispersion, at pH 7.1 ± 0.1, of a macromolecular binding agent. A anionic surface active agent (Sodium Lauryl Sulphate) is added to the aqueus phase to increase the wettability and smooth dispersion of Omeprazole.

The aqueus dispersion is sprayed on to the inert pellets in the cabin of a rotary type fluidized bed machine under aporopriate process parameters.

The content of active dispersion phase for one dose (one capsule) is as following.

Omeprazole **20 mg.**
Hydroxypropil methyl cellulose **5.3 mg.**
Lactose anhydrous **8 mg.**

L-Hydroxypropyl-cellulose **6 mg.**
Sodium lauryl sulphate **0.5mg.**
Disodium hydrogen phosphate dihydrate **0.8 mg.**
Water **0.21 ml.**

II Active coated pellets have to be protected from the organic solvent which is normally used to disperse or dissolve the enteric coating material.

The thickness of this layer is experimentally determined to obtain an optimal protection during the enteric coating processes and the necessary amount of coting material per capsule (one dose) for above mentioned active coated pellets (% 100 passes through 15 mesh sieves) has been determined as following.

HPMC **3.4 mg.**
Water **0.06 ml.**

Aqueus molecular dispersion of HPMC is sprayed under appropriate process parameters on to the active coated pellets in the cabine of a rotary type fludized bed machine and cried until the water content of the pellets is less than 1% when determined by the toluen distilation method described in USP XXII.

IV.Enteric coating is performed in the same machine using appropriate process parameters by spraying the following coating solution.

HPMC phytalate **24 mg.**
Diethyl phytalate **0.13 mg.**
Aceton **225 mg.(... ml)**
Ethyl alcohol **96 mg.(... ml)**

Finished product is sieved through 15 mesh and 20 mesh sieves. Pellets which pass through 15 mesh and are retained on 20 mesh sieves, are filled to gelatin capsules. Capsule contents are 233 mg ± 10%.

II Protective coating phase:

Machine: Glatt GPCG 60 with GRG 30
Active coated pellets: **25 kg ± 0.4**
Spray nozzle: **2 x 1.8 mn**
Nozzle position: **Tangential**
Filter type: **PB. (2% of cotton wod)**
Sieve type: **Rotor Disc.**
Inlet air Temperature: **50-60°C**
Inlet Air Rate: **700-800 m³/h**
Pumping rate: **20 rpm**
Slit width: **2 mm**
Rotor Speed: **300 rpm**

III Enteric coating phase:

Machine: Glatt GPCG 60 with GRG 30
Spray nozzle: **2 x 1.8 mm**
Nozzle position: **Tangential**
Filter type: **PB2**
Sieve type: **Rotor Disc**

[illegible] rpm
[illegible] 400-600 rpm

Claims

capsule, characterized in that the process is performed to obtain an inert core covered with the micronized active substance to be also enteric coated and dried after the adjusting of its granulometry, being in this way ready to be introduced as capsules.

2. A production method of pellets containing Omeprazole according to the previous claim, characterized in that the inert nucleous includes a 65-85% of sacarose, 15-25% of starch and 2-66% of glucose, said nucleous being obtained by conventional means and being sieved through a mesh within 0.71 and 0.85 mm.

3. A production method according to the first claim, characterized in that the active substance is micronized and sieved through a 150 mesh to be dispersed in a buffered aqueus dispersion at pH 7.1 ± 1% with the adition of an anionic surface active agent, as for example sodium lauril sulphate.

4. A production method according to the first claim, characterized in that the active substance comprising Omeprazole, hydroxil methyl cellulose, lactose anhydrous, L-hydroxy popyl-cellulose, sodium lauril sulphate, disodium hydrogen phosphate dihydrate and water is sprayed onto the inert pellets in the cabin of a rotary type fluidized bed machine.

5. A production method according to the first claim, characterized in that the enteric cover in produced in a fluidized bed with HPMC phytalate, diethyl phytalate, aceton and ethyl alcohol being afterwards dried to obtain a water content of less than 1%.

European Patent Office

EUROPEAN SEARCH REPORT

Application Number

EP 91 50 0066

DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)
Y,D	GB-A-2 189 698 (AKTIEBOLAGET HASSLE) * page 1, line 6 - line 8 * * page 2, line 25 - page 3, line 37 * * page 5 - page 6; example 2 * * page 6 - page 7; example 5 *	1,3-5	A61K9/54 A61K31/44
Y	DE-A-3 901 151 (HOECHST A.G.) * page 13; example 11 *	1,3-5	
A	EP-A-0 256 933 (ETHYPHARM) * page 2, line 61 - page 3, line 4 *	2	
A	EP-A-0 237 506 (LEJUS MEDICAL AKTIEBOLAG) * page 2, line 37 - line 43 * * page 3, line 13 - line 15 * * page 4; example 1 *	1-5	
			TECHNICAL FIELDS SEARCHED (Int. Cl.5)
			A61K

The present search report has been drawn up for all claims

EPO FORM 1503

X : particularly relevant if taken alone
Y : particularly relevant if combined with another document of the same category
A : technological background
O : non-written disclosure
P : intermediate document

T : theory or principle underlying the invention
E : earlier patent document, but published on, after the filing date
D : document cited in the application
L : document cited for other reasons

& : member of the same patent family, corresponding document